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Abstract Desmosomes are cell–cell adhesion sites and
part of the intercalated discs, which couple adjacent
cardiomyocytes. The connection is formed by the extra-
cellular domains of desmosomal cadherins that are also
linked to the cytoskeleton on the cytoplasmic side. To
examine the contribution of the desmosomal cadherin des-
moglein 2 to cardiomyocyte adhesion and cardiac function,
mutant mice were prepared lacking a part of the extracel-
lular adhesive domain of desmoglein 2. Most live born
mutant mice presented normal overall cardiac morphology
at 2 weeks. Some animals, however, displayed extensive
ﬁbrotic lesions. Later on, mutants developed ventricular
dilation leading to cardiac insufﬁciency and eventually
premature death. Upon histological examination, cardio-
myocyte death by calcifying necrosis and replacement by
ﬁbrous tissue were observed. Fibrotic lesions were highly
proliferative in 2-week-old mutants, whereas the ﬁbrotic
lesions of older mutants showed little proliferation indi-
cating the completion of local muscle replacement by scar
tissue. Disease progression correlated with increased
mRNA expression of c-myc, ANF, BNF, CTGF and
GDF15, which are markers for cardiac stress, remodeling
and heart failure. Taken together, the desmoglein 2-mutant
mice display features of dilative cardiomyopathy and
arrhythmogenic right ventricular cardiomyopathy, an
inherited human heart disease with pronounced ﬁbrosis and
ventricular arrhythmias that has been linked to mutations in
desmosomal proteins including desmoglein 2.
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Abbreviations
ARVC Arrhythmogenic right ventricular
cardiomyopathy
DSG2 Gene encoding Dsg2
Dsg2 Desmoglein 2 polypeptide
Introduction
The intercalated disc is a complex cell–cell attachment site
mediating mechanical and electrical coupling between
cardiomyocytes. It consists of adherens junctions, which
facilitate the attachment of the actin ﬁlament-containing
contractile apparatus and desmosomes, which serve as
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DOI 10.1007/s00395-011-0175-yanchorage sites for desmin intermediate ﬁlaments. Des-
mosomes are symmetric multiprotein assemblies with their
halves interconnected to transmit forces between adjacent
cells (reviews in [19, 21, 28]). At the core are calcium-
dependent adhesion proteins of the cadherin type that are
grouped into two families, the desmocollins and desm-
ogleins. In the heart, desmoglein 2 (Dsg2) and desmocollin
2 are by far the most prominent, if not sole desmosomal
cadherins [28]. These polypeptides interact in cis and trans
forming homo- and heteropolymers via their extracellular
domains EC1–EC4, the conﬁguration of which is inﬂu-
enced by calcium ion binding [13, 55, 59, 60]. It is assumed
that the insertion of tryptophane 2 into a hydrophobic
pocket of the EC1 domain and EC1–EC2 interactions are
important for multimerization and engagement in zipper-
like transcellular arrangements (e.g., [7] for C-cadherin),
which is supported by ultrastructural analyses [1, 23] and
antibody localization studies [53]. Desmosomal cadherins
are connected to cytoplasmic linker molecules, which are
localized to the desmosomal plaque. These linkers include
plakoglobin and the cell-type speciﬁcally expressed pla-
kophilins (cf. [19, 21, 28]). In the case of plakoglobin,
direct desmosomal cadherin binding sites have been iden-
tiﬁed (e.g., [12]). Desmoplakin, a member of the plakin
cytolinker family, is another major component of the des-
mosomal plaque. It binds to plakophilins and mediates
intermediate ﬁlament attachment to desmosomal junctions
[19, 21, 28].
Mutations of the genes encoding Dsg2, desmocollin 2,
plakoglobin, plakophilin 2 and desmoplakin are found in
approximately 50% of patients with arrhythmogenic right
ventricular cardiomyopathy (ARVC) [2, 24, 57]. Thus,
ARVC is considered to be a disease of the desmosome,
although other factors are also implicated [5, 20, 24, 39,
51, 58]. ARVC occurs at a frequency of 1:1,000 to
1:5,000 [3, 9] and leads to heart failure or sudden car-
diac death in young adults. Excessive dilation, predom-
inantly of the right ventricle, progressive ﬁbrofatty
replacement of cardiomyocytes and arrhythmias are the
main features of the disease (recent reviews [24, 57,
61]). Especially in patients carrying mutations in the
desmoplakin and DSG2 genes, the left ventricle is also
severely affected [17]. In addition, the V55M missense
mutation of the DSG2 gene predisposes to dilative car-
diomyopathy [48].
To analyze the impact of the adhesive extracellular
Dsg2 domains in demososme-related heart function,
mouse strains were established lacking exons 4–6 of the
DSG2 gene, which code for major parts of the EC1/EC2
domains. Homozygous mutant mice presented heart dis-
ease with necrotic cell death of cardiomyocytes, cardiac
ﬁbrosis and dilation of heart chambers leading to cardiac
dysfunction.
Materials and methods
DNA cloning
All synthetic oligonucleotides are listed in Table 1.A
targeting construct was prepared to conditionally delete
exons 3 and 4 of murine DSG2. First, the 50-homology
region between introns 3 and 6 was subcloned as a
5,483 bp HindIII-fragment from phage kMg1 (cf. [15]) into
pBluescript KS(?) resulting in clone 3001. A 50-loxP-site
was introduced by insertion of annealed oligomers loxP-f/
loxP-r into the NheI-site of intron 3 (clone 3007). A second
XhoI-site was then introduced by ligating annealed linkers
Eco-Xho-Bst-f/Eco-Xho-Bst-r into the EcoRI- and BstXI-
sites of clone 3007 (clone 3010). For cloning the 30-arm,
pBluescript II_SK(?) was ﬁrst modiﬁed by inserting
annealed linkers 03-51pBS2SK-EI?Sph-a/03-51pBS2SK-
EI?Sph-b into the EcoRI-site without reconstituting it
(clone 3000). Then, the *4.6 kb HindIII-fragment of
kMg1 was cloned into clone 3000 producing clone 3004.
To afford the usage of a 50-external probe that had been
used previously for Southern blot analyses [15], the SphI-
site at the 30-end of clone 3004 was removed by blunt-end
ligation after digestion with Bst1107I and SmaI resulting in
clone 3008. A construct with the neomycin-resistance
cassette (NFL) under control of the phosphoglycerate
kinase promoter and ﬂanked by two directed FRT-sites and
an additional loxP-site at the 30-end was provided by Dr.
Gale Martin. It was used for PCR-ampliﬁcation with
primers 05-251-Eco-PGK-Neo-f and 05-252-Eco-PGK-
Neo-r, which introduced EcoRI-sites at either end. The
EcoRI-endowed DNA was thereafter ligated into the
unique EcoRI-site of exon 6 in clone 3008, thereby creat-
ing clone 3009. Clones 3009 and 3010 were then digested
with XhoI and the appropriate genomic fragments were
ligated rendering the ﬁnal targeting construct (clone 3011).
Homologous recombination in embryonic stem cells
and preparation of transgenic strains
NotI-linearized clone 3011 was transfected into embryonal
stem cell strain W9.5 [56] by electroporation (single pulse,
500 lF,0.24 kV).G418-resistantcolonieswereisolatedand
subjected to Southern blot analyses. To this end, EcoRV-
digested and gel electrophoretically separated DNA was
blotted onto nylon membranes and hybridized with two
external and one internal (neomycin) probes that were gene-
rated by PCR. Primers 03-66_5ext_for/03-67_5ext_rev
wereusedforthe50-externalprobe,primers03-54_3ext_for/
03-72_3ext_rev2 for the 30-external probe, and primers
03-70_NeoProbe_for/03-71_NeoProbe_rev for the internal
neomycin probe (Table 1). The PCR products were labeled
with
32P-dATP by random primed oligo labeling
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123(Stratagene). Cell clones with correct recombination were
usedtopreparetransgenicanimals(cf.[15]).Chimericmales
were backcrossed with C57BL/6J females and the dark-
haired offspring was genotyped. To remove the NFL-cas-
sette, transgenic animals were crossed with FLP
e deleter
mice [49]. FLP-mediated recombination was assayed by
PCR (primers 03-57b and 03-58_30rev; Table 1) and
Southern blot analyses. Animals with correctly recombined
alleles were intercrossed with the constitutively Cre-
expressing ‘‘ActCre’’ strain FVB/N-TgN(ACTB-Cre)2Mrt
from Jackson Laboratories [38] to generate constitutively
mutant animals.
For experimental analyses, heterozygous animals were
crossed to produce wild-type and heterozygous littermate
controls. Unfortunately, mutant offspring was often absent
becauseofthesmallaveragelittersizeofsixtoeightanimals
andthe approximately70%reductionofmutant animals due
to intrauterine lethality. As an alternative, heterozygous
females were crossed with homozygous males, which was
more efﬁcient but lacked wild-type controls. Consequently,
intheexperiments,age-matchedcontrolshadtobeusedfrom
parallel breedings. Analyzed mice still possess a mixed
genetic background. To reduce genetic variability, mutant
mice were backcrossed with C57BL/6J mice.
Table 1 List of synthetic oligonucleotides
Name Sequence (50–30)
loxP-f CTAGAAGCTTATAACTTCGTATAATGTATGCTATACGAAGTTATGATATC
loxP-r CTAGGATATCATAACTTCGTATAGCATACATTATACGAAGTTATAAGCTT
Eco-Xho-Bst-f AATTCCGGCTCGAGATACCGCG
Eco-Xho-Bst-r GTATCTCGAGCCGG
03-51pBS2SK-EI?Sph-a AGCTTGATATCGCATGCCTGCA
03-51pBS2SK-EI?Sph-b GGCATGCGATATCA
05-251-Eco-PGK-Neo-f GCCGGAATTCGCTGCGATTATAGGCCTGAG
05-252-Eco-PGK-Neo-r GATCGAATTCGCGGGGATAATACGACTC
03-57b GATCAGCAGCCTCTGTTCC
03-58_30rev GTGTCACCAGGGATAGTC
03-66_5ext_for GATGTGGGAGGCTTAAGAG
03-67_5ext_rev GTGCTGCGACCCTTTAATC
03-54_3ext_for AGCATGCATAGAGGCAAATTC
03-72_3ext_rev2 CTGCCATTCCAGGAAATGC
03-70_NeoProbe_for AGGCTATTCGGCTATGAC
03-71_NeoProbe_rev GAGCTGGCCCTTAATTTG
07-12-f CCAGAAAGAACCCGATTG
07-13-r GATCCGCATGACTTCTAC
05-31-GAPDH-f ATGAGCCCTTCCACAATG
05-32-GAPDH-r TCCACTCACGGCAAATTC
HMBS-f TCCCTGAAGGATGTGCCTAC
HMBS-r AAGGGTTTTCCCGTTTGC
ANF-f CACAGATCTGATGGATTTCAAGA
ANF-r CCTCATCTTCTACCGGCATC
BNF-f GTCAGTCGTTTGGGCTGTAAC
BNF-r AGACCCAGGCAGAGTCAGAA
c-myc-f CCTAGTGCTGCATGAGGAGA
c-myc-r TCTTCCTCATCTTCTTGCTCTTC
CTGF-f TGACCTGGAGGAAAACATTAAGA
CTGF-r AGCCCTGTATGTCTTCACACTG
GDF15-f GAGCTACGGGGTCGCTTC
GDF15-r GGGACCCCAATCTCACCT
RGS2-f GAGAAAATGAAGCGGACACTCT
RGS2-r TTGCCAGTTTTGGGCTTC
bMHC-f TGAAGCTGACGCAGGAGAG
bMHC-r TGAGTGCATTTAACTCAAAGTCCT
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The sequences of all primers are listed in Table 1. For
analysis of DSG2 mRNA expression, RNA was isolated
from snap frozen heart tissue (RNeasy-Kit, Qiagen, Hilden,
Germany). As much as 0.5 lg of total RNA was tran-
scribed with Omniscript reverse transcriptase (Qiagen) and
1/4 of the cDNA was used as template for secondary strand
synthesis with primers 07-12-f and 07-13-r, generating
fragments of either 210 bp (recombined) or 686 bp (wt).
GAPDH was used as control (primers 05-31-GAPDH-f and
05-32-GAPDH-r).
For all other mRNA analyses, total RNA was isolated
with the High Pure RNA Tissue Kit (Roche, Mannheim,
Germany); 25 mg tissue was homogenized with a glass–
Teﬂon homogenizer in 900 ll lysis-/binding buffer and
subjected to extraction with phenol/chloroform/isoamyl
alcohol (Applied Biosystems, Darmstadt, Germany). As
much as 1 lg of the afﬁnity column-puriﬁed RNA was
reverse transcribed into cDNA using the Transcriptor First
Strand cDNA Synthesis Kit (Roche) with the oligo-(dT)15
primer.
Real-time PCR was performed with a LightCycler
(Roche) using the LightCycler TaqMan Master Kit (Roche).
Forward and reverse primers and corresponding TaqMan
probes were selected with the help of the Universal Pro-
beLibrary Assay Design Center (Roche). They are listed in
Table 1 as the following pairs HMBS-f/HMBS-r (UPL#79),
ANF-f/ANF-r (UPL-#25), BNF-f/BNF-r (UPL#71), c-myc-
f/c-myc-r (UPL#77), CTGF-f/CTGF-r (UPL#71), GDF15-f/
GDF15-r (UPL#62), RGS2-f/RGS2-r(UPL#6), and bMHC-
f/bMHC-r (UPL#85). PCR programs were operated by the
LightCycler Software Version 3.5. cDNA (2 ll) prepared
from 100 ng total RNA was used in each PCR with only
water and 100 ng RNA as negative controls. HMBS was
used as housekeeping control [22]. Each tissue sample was
examined in duplicate. To determine PCR efﬁciency, a
coefﬁcient ﬁle was created for each target cDNA and the
housekeeping control. Quantitative analyses of cardiac
target mRNA expression were performed with the RelQuant
Software, Version 1.01 (Roche).
Histology and immunohistochemistry
Hearts were ﬁxed in PBS containing 4% formaldehyde,
washed and embedded in parafﬁn; 8-lm thick tissue sec-
tions were stained with hematoxylin/eosin, Kossa and
Heidenhein (azan).
For immunohistochemistry, 5-lm thick parafﬁn sections
were prepared. The sections were rehydrated, heated in
citrate buffer (pressure cooker, 121C, 3 min), cooled
down for 20 min and incubated with primary antibodies
against the extracellular anchor and EC4 domains of
murine Dsg2 1:500 or 1:1,000 [50] and desmoplakin
(1:1,000 or 1:2,000, Progen, Heidelberg, Germany) over-
night at 4 C. After washing in 50 mM Tris/HCl, 0.3 M
NaCl, 0.05% Tween 20, pH 7.5, the sections were incu-
bated for 1 h at room temperature with the secondary
antibodies (Alexa488-conjugated goat anti rabbit antibod-
ies [1:500] and Cy3-conjugated afﬁnity puriﬁed goat
anti-guinea pig antibodies [1:400; both from Dianova,
Hamburg, Germany]). After three washing steps, auto-
ﬂuorescence was quenched with 0.1% Sudan black in 70%
ethanol (30 min). The sections were counterstained with
DAPI. Fluorescence micrographs were recorded with an
LSM710 DUO (Zeiss, Jena, Germany). For quantiﬁcation,
non-saturating dilution ranges were determined for the
primary antibodies. Quantiﬁcation of intercalated disc
staining was done for 40 intercalated discs per animal using
the ZEN 2009-Software (Zeiss, Jena, Germany). The ratio
of Dsg2- to desmoplakin-ﬂuorescence was calculated for
each intercalated disc and the mean value of the ratio of all
intercalated discs of each studied animal was determined.
Peroxidase reaction was used for detection of Ki67
(rabbit mAb, Medac, Wedel, Germany) and cleaved cas-
pase 3 (Cell Signaling Technology, Danvers, MA). Bound
primary antibodies were detected with the ZytoChemPlus
HRP Polymer anti-Mouse/Rabbit Kit (Zytomed Systems,
Berlin, Germany). Parafﬁn sections of 5-lm thickness were
deparafﬁnized in xylene and rehydrated in a graded alcohol
series. During rehydration, the activity of the endogenous
peroxidase was blocked by treating sections with 3% H2O2
in 70% ethanol for 10 min in the dark. Antigen retrieval
was achieved by incubating sections in 10 mM citrate
buffer (pH 6.0) at 94C for 40 min (Ki67) or in a pressure
cooker for 3 min at 121C (cleaved caspase-3). Cooled
down sections were treated with blocking solution of the
HRP Polymer Kit. Then, sections were incubated for 2 h at
room temperature with the Ki67-antibody (1:200) or
overnight at 4C with the cleaved caspase 3-antibody
(1:300). After subsequent washing, the sections were
covered with the HRP-polymer for 30 min. The AEC
Substrate Kit (Invitrogen, Karlsruhe, Germany) was
applied to visualize the immunoreaction and sections were
counterstained with hematoxylin. The percentage of Ki67-
positive interstitial cells was counted by two independent
and blinded observers (CAK and SK). The percentage of
Ki67-positive interstitial cells was assessed in three to four
randomly chosen areas of the right and left ventricular
wall, as well as in the septum at a magniﬁcation of 4009.
Cell fractionation and immunoblotting
Fresh tissue fragments were minced by extensive homo-
genization in extraction buffer I (10 mM Tris–HCl, pH 8,
2 mM MgCl2, 10 mM KCl, 0.1% SDS, 0.05% PMSF
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Mannheim, Germany) per 10 ml buffer) at 4C. After
shaking for 1 h at 4C, the homogenate was centrifuged at
17,0009g for 25 min at 4C. The cytosolic supernatant
fraction was removed and the pellet was washed three times
with extraction buffer. The pellet was then dissolved by
shaking in extraction buffer I supplemented with 2% SDS
for 2 h at 4C. After centrifugation (17,0009g, 25 min,
4C), the supernatant was used for immunoblotting. Protein
concentration was determined by Lowry assay (Roth, Karls-
ruhe, Germany). Proteins were separated by standard SDS
polyacrylamide gel electrophoresis and blotted onto PVDF
membranes. Antibodies against Dsg2 (rabbit polyclonal
1:1,000; [50]), b-actin (rabbit polyclonal, A2066, 1:4,000,
Sigma, Steinheim, Germany), desmocollin 2 (goat; 1:200;
Santa Cruz Biotechnology, Santa Cruz, USA) and desmo-
plakin (mouse; Progen, Heidelberg, Germany) were diluted
inTBSTsupplementedwith5%BSAandincubatedwiththe
membrane overnight at 4C. After three washes in TBST,
the membrane was incubated for 1 h with HRP-coupled
secondary antibodies from DAKO (diluted 1:3,000 in TBST
containing 5% milk powder). The ECL system was used for
HRP detection (GE Healthcare, Freiburg, Germany).
Echocardiography
Cardiac images were acquired using a Vevo770 high-reso-
lution ultrasound scanner with 30-MHz linear transducer
(VisualSonics Inc.). Echocardiography was performed
under slight mask anesthesia by an inhaled mixture of 1.5%
(v/v) isoﬂurane and 100% oxygen. ECGs were obtained
with built-in ECG electrode-contact pads. Body tempera-
ture was maintained at 37C by a heating pad. All hair was
removed from the chest using a chemical hair remover
(Nair; Carter-Horner; Mississauga, Canada). Aquasonic
100 gel (Parker Laboratories, Hellendoorn, The Nether-
lands) from which air bubbles had been expelled was
applied to the thorax surface to optimize the visibility of
the cardiac chambers. Parasternal long-axis and short-axis
views were acquired. Image data obtained from multiple
cardiac cycles were retrospectively assembled into a rep-
resentative image sequence of over 100 images per cardiac
cycle using the ECG-based Kilohertz Visualization (EKV)
capability of the Vevo770 scanner. The EKV images are
synchronized with respect to the ECG signal. Left ven-
tricular (LV) end-systolic and end-diastolic volumes (ESV
and EDV) were calculated by identiﬁcation of frames with
maximal and minimal cross-sectional area and width. The
system software employs a formula based on a cylindric-
hemiellipsoid model [66]. LV ejection fraction (LVEF),
cardiac output (CO), stroke volume (SV) and fractional
area change (FAC) were calculated from volume data.
M-mode recordings were analyzed for wall thicknesses and
chamber dimensions. Fractional shortening (FS) was
assessed as a measure of left ventricular systolic function.
The Doppler transducer was positioned over the apex
(apical four-chamber view) for sampling of the mitral ﬂow
wavefrom at the tips of the mitral valves. LV diastolic
function was evaluated from the E/A ratio of Doppler
tracings, where E is the peak velocity of early diastolic
ventricular ﬁlling, and A is the peak velocity of late ﬁlling
associated with atrial contraction. A single ultrasound
session ranged from 15 to 30 min per mouse.
Hemodynamic measurement of left ventricular function
and ECG measurements
Invasive hemodynamics were assessed using a 1.4F Millar
pressure–volume catheter (SPR-839, Millar Instrument,
Houston, Texas) placed into the left ventricle through the
right carotid artery. After surgical instrumentation, data
were analyzed with the IOX Software (EMKA) to calculate
left ventricular developed pressure (LVDP), and the ﬁrst
derivatives of left intraventricular pressure (rate of pressure
development ? dP/dtmax and rate of pressure decrease -
dP/dtmin). Cardiac contractility index was calculated as
?dP/dtmax normalized for the respective LVDP. Relaxation
index was calculated as the ratio of -dP/dtmin to respective
LVDP [40]. To assess the catecholamine responsiveness,
cardiac variables were recorded under continuous norepi-
nephrine administration (0.4 lg/kg/min, i.p.). For ECG
measurements, four lead surface ECGs were recorded
before and during norepinephrine administration. There-
fore, ECG electrodes were attached to each limb. The
resulting ECGs were analyzed with the IOX Software
(EMKA). At the end of the experiments, mice were killed
by cervical dislocation.
Statistical analysis
Results are presented as mean ± SD (echocardiography) or
as mean ± SEM (all other assessments). In cases, in which
two groups were compared (echocardiography and RT-
PCR of 2-week-old mice), data were analyzed by the
unpaired Student’s t test. P values\0.05 were considered
to be statistically signiﬁcant. To analyze the results of three
experimental groups, one way ANOVA and post hoc
Bonferroni’s multiple comparison tests were used.
Results
Generation of DSG2-mutant mice
A targeting construct was prepared for inducible deletion
of exons 4–6 of murine DSG2 (Fig. 1a). This mutation
Basic Res Cardiol (2011) 106:617–633 621
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Dsg2 (Dsg2
mt) that lacks a substantial segment of the EC1–
EC2 domains, which are believed to participate in homo-
and heterophilic desmosomal cadherin interactions
(Fig. 1b; cf. [28, 59]). Transgenic mice were prepared from
embryonal stem cells after homologous recombination of
the targeting construct. The neomycin-resistance cassette
was then removed with the help of Flp
e deleter mice
(Fig. 1a) [8]. The resulting DSG2
loxP/loxP offspring pre-
sented no obvious phenotypic deﬁciency. To investigate
the consequences of constitutive DSG2 mutation, DSG2
loxP
animals were crossed with transgenic mice producing Cre-
recombinase under b-actin promoter control [38]. This led
to deletion of exons 4–6 of DSG2 in germ cells and sub-
sequent transmission of the mutated allele to the offspring.
In contrast to the previously described DSG2 null mutants
lacking exons 7 and 8, all of which died around implan-
tation [15], approximately a third of the DSG2
mt/mt mice
lacking exons 4–6 were born apparently healthy, whereas
the rest died during intrauterine development. DSG2
mt
Fig. 1 Preparation of DSG2-mutant mice. a An EcoRV (EV)-
segment of the DSG2 wild-type allele (DSG2
wt) extending between
introns 1 and 8 is depicted at the top. Homologous recombination
within this segment leads to the DSG2
loxP-neo allele including loxP
sites in introns 3 and 6 and an FRT-ﬂanked neomycin-resistance
cassette (NFL) in intron 6. Flp-mediated excision of NFL results in
allele DSG2
loxP. Further recombination by Cre-recombinase generates
the mutant allele DSG2
mt. Gene regions corresponding to the
sequences provided by the targeting construct are indicated by solid
lines, and adjoining endogenous gene regions by dotted lines.
b Scheme depicting wild-type and mutant Dsg2 (Dsg2
wt, Dsg2
mt).
Dsg2
mt lacks parts of the extracellular EC1 and EC2 domains. The
scheme further depicts the aminoterminal precursor-speciﬁc segment
P, the four *110 amino acid-long extracellular calcium-binding
domains EC1–EC4, the extracellular anchor domain EA, transmem-
brane domain TM, intracellular anchor domain IA, intracellular
catenin-binding and cadherin-like sequence ICS, proline-rich linker L,
the repeated unit domain RUD and the carboxyterminal tail
T. c Detection of mutated DSG2 mRNA. RNA was prepared from
DSG2 wild-type and mutant mice (DSG2
wt, DSG2
mt). GAPDH
mRNA was ampliﬁed as control. d Analysis of Dsg2 expression by
immunoblotting shows a protein band at *160 kDa in the DSG2
wt/wt
and of *110 kDa in DSG2
mt/mt mice. The signiﬁcant difference in
mobility is due to deletion of the single glycosylation site. The
calculated molecular weight for wild-type Dsg2 is 122,398 and for
mutant Dsg2 104,703. Desmocollin 2 (Dsc2), desmoplakin (Dsp) and
b-actin served as loading controls. e Immunohistochemistry reveals
correct targeting of Dsg2
mt to intercalated discs (arrowheads),
although expression levels are reduced in DSG2
mt/mt mice (same
magniﬁcation in all images; scale bar, 20 lm). The quantiﬁcation was
done for four wild-type and four mutant 2-week-old littermates from
two litters analyzing the ratio of Dsg2 to desmoplakin ﬂuorescence
for 40 intercalated discs in each animal
622 Basic Res Cardiol (2011) 106:617–633
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mt protein are produced in these mice
(Fig. 1c, d). Furthermore, Dsg2
mt is located in intercalated
discs (Fig. 1e). Dsg2
mt expression, however, is consider-
ably lower than that of the wild type (Fig. 1d, e).
Cardiac dilation, enlargement and functional
deﬁciencies in DSG2-mutant mice
Echocardiography was performed in 15- to 26-week-old
maleanimals(summaryofallresultsinTable 2).DSG2
mt/mt
mice exhibited dilation of the left ventricle (increased
diameters in M-mode in Fig. 2a, b) and an elevated end-
diastolic volume (Table 2). Elevated end-diastolic volume
indicated reduced ventricular compliance. In accordance,
early left ventricular ﬁlling had a tendency to be slower in
DSG2
mt/mt mice (mitral valve E-wave peak), whereas late
diastolic blood ﬂow velocity across the mitral valve was
signiﬁcantly reduced (mitral valve A-wave peak). Conse-
quently, the E-wave to A-wave (E/A) ratio was signiﬁcantly
increased in the mutants, indicating impaired ventricular
ﬁlling. In addition, systolic left ventricular diameter and
systolic left ventricular end volume were increased in
mutants indicating altered systolic function. Furthermore,
ejection fraction, cardiac output and fractional shortening
were all reduced (Table 2). Heart rates were comparable
between wild type and mutants. Hemodynamic parameters
were invasively examined by micro-conductance catheter to
complement non-invasive echocardiography (see Table 2).
In agreement with the impaired systolic function observed
by echocardiography, left ventricular developed pressure
(LVDP), the maximal rate of left ventricular pressure
change (dP/dtmax), a parameter of cardiac contractility and
the contractility index [40] were decreased in DSG2
mt/mt
mice (Table 2). Subjecting animals to stress by treatment
with norepinephrine demonstrated that mutant hearts were
still responsive, resulting in increase of LVDP, dP/dtmax and
contractility index, albeit not to the extent of their wild-type
counterparts (Table 2). Reﬂecting diastolic dysfunction, left
ventricular relaxation was signiﬁcantly impaired with
reduced -dP/dtmin and relaxation index. Under norepi-
nephrine stimulation, the mutant mice developed ventricu-
lar arrhythmias, e.g., ventricular extrasystoles, as well
as atrial arrhythmias and repolarization abnormalities
(Fig. 2f). One of the mutant animals died during anesthesia.
ECG alterations were not recorded in any of the age- and
sex-matched wild-type animals in the presence of norepi-
nephrine (Fig. 2e).
Anatomically, dilation of both ventricles and in some
cases also dilated atria were readily apparent in dissected
female and male mutants (Figs. 2d, 3a, b). Furthermore,
heart weight was signiﬁcantly increased (Table 2). In one
case of sudden death, rupture of the right ventricle was
detected. Anatomical, histological and clinical parameters
did not change upon successive inbreeding and back-
crossing against C57BL/6J (online resource 1 and 2;
unpublished data).
Development of pronounced ﬁbrosis in DSG2-mutant
mice
In dissected hearts of mutant mice, ﬁbrotic lesions of
various size and different shapes, often in the form of
striations, were frequently seen. In some instances, the
entire ventricular wall was completely replaced by ﬁbrotic
scar tissue resulting in substantial wall thinning (e.g.,
Fig. 4b, d). Kossa-positive calciﬁcations were often found
in ﬁbrotic lesions and scars (Fig. 3c). Furthermore, groups
of cardiomyocytes embedded in ﬁbrous tissue and cardio-
myocytes with dysmorphic nuclei were noted (Fig. 3d).
Histological analyses further revealed different degrees of
ﬁbrosis in both ventricular walls and the septum (Fig. 4b,
d, f). Staining with azan and anti-vimentin antibodies fur-
ther supported these ﬁndings (e.g., Fig. 4h, j). Extensive
inﬁltrates of immune cells were not seen except for scat-
tered immune cells in a few regions.
Next, proliferation of interstitial cells faraway from
ﬁbrotic lesions and proliferation within ﬁbrotic lesions was
studiedat2,8and13 weeksbyKi67immunohistochemistry
(Fig. 5). No differences in interstitial cell proliferation were
detectable between DSG2
wt/wt, DSG2
wt/mt and DSG2
mt/mt at
2 weeks (Fig. 5a–c). At 8 weeks, the proliferation index of
interstitial cells was elevated in all segments of the ven-
tricular walls of DSG2
mt/mt mice compared to DSG2
wt/wt
animals (P\0.05; Fig. 5d–f, k, l). Then, at 13 weeks, the
percentage of proliferating cells did not differ between
mutant and wild-type animals anymore (Fig. 5g–i).
Contiguous ﬁbrotic lesions were examined next. A
subset of DSG2
mt/mt mice presented extensive lesions with
necrotic calcinosis already at 2 weeks (Fig. 6c, f). Fur-
thermore, cells expressing activated caspase-3 were also
observed indicating apoptotic cell death (Fig. 6i). Signiﬁ-
cantly elevated Ki67-staining was detected within these
lesions (54.4 ± 5.6%; Fig. 5 m) in comparison to inter-
stitial cells in areas away from the lesion or in age-matched
DSG2
wt/wt and DSG2
wt/mt hearts (P\0.0001). Of note, the
number of proliferating cells within such lesions was sig-
niﬁcantly higher in 2-week-old than in 8- and 13-week-old
animals (Fig. 5j, m–o). The cells within the lesions were
rounded in young animals and spindle shaped in the older
mice (compare, Fig. 5m–o).
Sequential induction of cardiac stress and heart failure
markers in DSG2-mutant mice
The expression of well-established cardiac stress and heart
failure markers [14, 16] was examined at 2, 8 and 13 weeks
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123by real time RT-PCR to assess the consequences of DSG2
mutation at the molecular level. At 2 weeks, cardiac con-
nective tissue growth factor (CTGF) mRNA was signiﬁ-
cantly upregulated. In addition, growth differentiation
factor 15 (GDF15) and c-myc mRNA were increased
(Fig. 7). When 2-week-old DSG2
mt/mt mice were further
subclassiﬁed by visual inspection into those without and
those with ﬁbrotic lesions, signiﬁcantly elevated GDF15
mRNA expression was found in the hearts with ﬁbrotic
lesions (3.83 ± 1.42 vs. 0.18 ± 0.03 arbitrary units;
Table 2 Clinical measurements reveal deﬁciencies in right and left ventricular functions of DSG2
mt/mt mutant mice
DSG2
wt/wt DSG2
mt/mt
n 87
Body weight (g) 32.16 ± 2.06 33.89 ± 2.69
Heart weight (mg) 174.16 ± 16.34 221.66 ± 13.19***
Heart weight/body weight 5.41 ± 0.22 6.59 ± 0.69**
Heart length (apex basis, mm) 4.76 ± 0.2 5.55 ± 0.48**
Heart rate (beats/min) 502.75 ± 67.87 456.83 ± 38.45
M-mode variables
Left ventricle (LV) mass (mg) 115.48 ± 24.49 186.85 ± 80.66*
LV mass/body mass (mg/g) 3.57 ± 0.65 5.5 ± 2.26*
Interventricular septum in diastole (mm) 0.71 ± 0.07 0.79 ± 0.1
LV inner diameter in diastole (mm) 4.28 ± 0.49 5.23 ± 1.15 (P = 0.05)
LV posterior wall in diastole (mm) 0.73 ± 0.18 0.77 ± 0.12
Interventricular septum in systole (mm) 1.01 ± 0.13 0.90 ± 0.12
LV inner diameter in systole (mm) 2.68 ± 0.48 4.39 ± 1.23**
LV posterior wall in systole (mm) 1.12 ± 0.34 0.98 ± 0.18
Fractional shortening (%) 37.77 ± 4.59 16.98 ± 5.19***
B-mode variables
Ejection fraction (%) 67.00 ± 5.18 34.43 ± 11.28***
Cardiac output (ml/min) 24.73 ± 3.57 17.43 ± 2.79**
Stroke volume (ll) 50.81 ± 7.51 37.97 ± 6.67**
Fractional area change (%) 52.46 ± 8.48 23.82 ± 8.83***
End-diastolic volume (ll) 76.33 ± 14.41 121.82 ± 49.70*
End-systolic volume (ll) 26.61 ± 8.89 83.85 ± 48.17**
End-diastolic volume index (ll/g) 2.37 ± 0.44 3.61 ± 1.47*
End-systolic volume index (ll/g) 0.82 ± 0.26 2.49 ± 1.4***
Doppler wave form
Mitral valve E-wave peak (cm/s) 785.64 ± 105.67 739.62 ± 153.82 (P = 0,05)
Mitral valve A-wave peak (cm/s) 557.31 ± 144.52 244.25 ± 135.75**
Mitral valve E/A 1.46 ± 0.27 3.77 ± 2.01***
Invasive hemodynamics
Left ventricular developed pressure (LVDP)baseline 104.00 ± 3.81 92.71 ± 5.57**
LVDPnorepinephrine 120.00 ± 7.95 105.99 ± 9.66*
?dP/dtmax baseline 13,568.75 ± 865.77 9,522.14 ± 1,778.36***
?dP/dtmax norepinephrine 16,959.37 ± 1,311.36 11,916.14 ± 2,293.64***
-dP/dtmin baseline -9,147.13 ± 1,209.85 -6,376.58 ± 927.54**
-dP/dtmin norepinephrine -9,958.25 ± 1,293.03 -7,450.29 ± 1,218.84**
Relaxation indexbaseline -87.92 ± 10.81 -68.50 ± 6.80**
Relaxation indexnorepinehrine -83.09 ± 10.30 -70.09 ± 8.64*
M-mode and B-mode measurements indicate left ventricular dilatation in the mutant mice accompanied by decreased systolic function (echo-
cardiography and invasive hemodynamics). Note the decreased left ventricular compliance and impaired left atrial contractility. Late diastolic
velocity was reduced with consequently increased E/A; (wild-type DSG2
wt/wt vs. DSG2
mt/mt mutants *P\0.05, **P\0.01, ***P\0.001;
mean ± SD)
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123Table 3). This suggests that GDF15 mRNA expression is
an early indicator of disease progression.
At 8 and 13 weeks, CTGF, GDF15 and c-myc mRNA
are all signiﬁcantly upregulated in the mutant animals
(Fig. 7). In addition, the mRNA of atrial natriuretic peptide
(ANF) and B-type natriuretic factor (BNF), which were not
any different from the wild type at 2 weeks, were also
signiﬁcantly increased in DSG2
mt/mt mice at these later
time points (Fig. 7). Furthermore, cardiac b-myosin heavy
chain (bMHC) mRNA, a marker of the fetal gene program
[54],wasfoundtobesigniﬁcantlyupregulated inDSG2
mt/mt
mice at 8 weeks (0.18 ± 0.04 vs. 1.58 ± 0.52 arbitrary
Fig. 2 Homozygous DSG2-
mutant mice (DSG2
mt) present
ventricular dilation and signs of
compromised cardiac function.
a, b Representative
echocardiography (pictures
taken in B-mode) at the end of
diastole in wild-type (DSG2
wt)
male mice compared to age-
matched male DSG2
mt mice. RV
right ventricle, LV left ventricle,
IVS interventricular septum,
LVPW left ventricular posterior
wall, LVID left ventricular inner
diameter, ao aorta, pm papillary
muscle. c, d Comparison of the
morphology of a wild-type
(c) and a DSG2-mutant heart
(d), which presents an enlarged
right ventricle and extensive
ﬁbrotic lesions (arrows).
e, f Representative ECGs from
wild-type (e) and mutant mice
(f). Note the abnormalities in
the ECGs of the mutant mice
presenting extrasystole,
arrthythmia and conduction
abnormalities (f, from top to
bottom)
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123units; P = 0.0555) and 13 weeks (1.45 ± 0.06 vs. 2.51 ±
0.29 arbitrary units; P = 0.0095). In contrast, cardiac
RGS2 mRNA expression did not differ or tended to be
lower in mutants at the studied ages (Fig. 7). mRNA
expression of the various markers was not different
between wild-type and heterozygous mutant animals at 8
and 13 weeks, which was in line with the absence of
changes in morphology and proliferation (e.g., Fig. 5).
Discussion
DSG2
mt/mt mice, which lack major parts of the adhesive
extracellular domains EC1 and EC2, develop cardiac
ﬁbrosis, ventricular dilation, arrhythmia and cardiac
insufﬁciency. In other Dsg2-producing tissues such as
intestinal mucosa, liver and endometrium no overt patho-
logical alterations were observed. Yet, the majority of
Fig. 3 Cardiac morphology and
histology of 13-week-old male
DSG2
mt/mt mice. Note the
pronounced dilation of the heart
chambers in (a, b) and the
dilated atria (arrows in a).
c Representative Kossa stain of
an area in the ventricular wall
marked by rectangles in b. The
black silver deposits within such
a ﬁbrotic lesion indicate the
presence of calciﬁed, necrotic
cardiomyocytes.
d Representative hematoxylin/
eosin stain of an area with
cardiomyocytes surrounded by
ﬁbrous tissue. Note the
dysmorphic nuclei of
cardiomyocytes (arrowheads)
adjacent to ﬁbrocytes. Scale
bars: 5 mm in a, same
magniﬁcation in b; 200 lmi nc,
same magniﬁcation in d
Fig. 4 DSG2 mutation induces ﬁbrosis in both ventricles. Hearts
were dissected from wild-type and mutant mice carrying two DSG2
mt
alleles. Histological sections were either stained with hematoxylin/
eosin (a–f) and azan (g, h) or were incubated with antibodies directed
against the connective tissue marker vimentin and processed for
indirect immunoﬂuorescence microscopy (i, j). Note the increased
presence of connective tissue in DSG2
mt/mt mice. In addition to
diffuse ﬁbrosis, large ﬁbrotic scars are visible in the ventricular walls
(arrows in b). The magniﬁcation is the same in a and b, c–f (scale bar
in d, 100 lm) and g–j (scale bar in h, 100 lm)
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123mutants do not survive until birth and we are presently
trying to identify the critical developmental stages. Of note,
all mutants that were born displayed normal heart mor-
phology and all of them developed the described cardiac
phenotype. These DSG2
mt/mt mice expand currently
available murine models of desmosome-related dilative
cardiomyopathy (DCM) and ARVC [18, 33, 47, 65]. They
allow, for the ﬁrst time, to study the consequences of a
Fig. 5 Proliferation (Ki67 immunohistochemistry) of interstitial cells
is transiently increased in 8-week-old DSG2
mt/mt mice and in ﬁbrotic
lesions of young mutant animals. The data in a–j (mean ± SEM)
were obtained from three to four animals from parallel breedings at
each time point. At the age of 2 weeks only two mt/mt animals were
available for sampling from left and right ventricles because of large
ﬁbrotic foci in the ventricular wall. Proliferation of interstitial cells
detected by Ki67 immunohistochemistry in 2- (a–c) and 13-week-old
mice (g–i) was not signiﬁcantly different between wild-type (wt/wt),
heterozygous (wt/mt) and homozygous mutant animals (mt/mt).
Results of ANOVA: a P = 0.8729, b P = 0.9394, c P = 0.3574,
g P = 0.4773, h P = 0.3932, i P = 0.2726. d–f In 8-week-old
DSG2
mt/mt mice, proliferation of interstitial cells is signiﬁcantly
elevated compared to wild-type animals (*P\0.05; **P\0.01;
***P\0.001; ANOVA and post hoc Bonferroni tests). j The
histogram shows that the number of Ki67-positive cells in ﬁbrotic
lesions is signiﬁcantly higher in 2-week-old DSG2
mt/mt mice than in
8- and 13-week-old mutant mice (***P\0.001). k, l Comparison of
Ki67-staining in septum of 8-week-old DSG2
mt/mt (k) and DSG2
wt/wt
(l). Lesion of a 2-week-old (m) and a 13-week-old DSG2
mt/mt mouse
(n; S scar). o Small ﬁbrotic foci with an increased number of Ki67-
positive cells were observed occasionally in 8- to 13-week-old
mutants. Arrowheads in k, l, n and o mark Ki67-positive cells. Scale
bar in o, 100 lm (same magniﬁcation in k–o)
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123mutated endogenous desmosomal protein. The deleted
parts of the EC1 and EC2 domains are also affected by
mutations in human ARVC and DCM patients [2, 4, 48,
51]. Of note, the pathogenesis of the human diseases is
considered to occur in most instances in a dominant-
negative fashion [2, 24]. While this may also be the case in
the mutant mice, e.g., by altered interactions of the mutant
Dsg2, the reduced expression of mutant Dsg2 and its cor-
rect targeting to desmosomes argue in favor of a hypo-
morphic, i.e., loss of function phenotype.
The rationale for deleting a segment of the EC1–EC2
domains was based on the alleged importance of these
regions for efﬁcient desmosomal delivery and adhesive
interactions. The deleted region encompasses the single
N-glycosylation site and one of the four calcium-binding
pockets. Although glycosylation may affect trafﬁcking of
desmogleins [46], it appears to be of no or only minor
importance in our animal model, since the mutant Dsg2 is
delivered to desmosomes. The same is also observed in
cDNA-transfected cell lines, in which we do not ﬁnd a
signiﬁcantly elevated ER- or Golgi localization of the
mutant Dsg2 in comparison to its wild-type counterpart
[27]. Although the conserved aminoterminal ‘‘tryptophane
2’’, which has been implicated in cis and trans interactions
in other cadherins, is still present in the mutant Dsg2, its
hydrophobic binding pocket is deleted (cf. [59]). Other
amino acids that are probably involved in cadherin–cad-
herin interactions are also missing [7, 52, 59]. Most
importantly, the overall shortening of the extracellular
domains in combination with the loss of calcium binding,
which is presumably involved in stabilization of the EC
domains [42, 44, 52], is expected to lead to reduced EC
domain overlap for homophilic cis and trans interactions
[7, 10, 28, 52, 59]. Heterophilic interactions with desmo-
collin 2 may be affected in a similar way. Taken together,
decreased transcellular ﬂexibility and adhesion would be
expected in tissues producing the mutant Dsg2. Further in
vivo evidence for the importance of the EC1/EC2 domains
can be derived from observations in human diseases. Thus,
the deleted Dsg2 domains contain epitopes corresponding
Fig. 6 Two-week-old DSG2
mt/mt mice present variable cardiac
phenotypes. In situ images of hearts (a–c), Kossa stains of histological
sections (d–f) and cleaved caspase 3-immunohistology (g–i) are
shown for heterozygous DSG2
mt/wt mice (a, d, g) and for homozygous
DSG2
mt/mt mice either without visible ﬁbrotic foci (b, e, f) or with
extensive ﬁbrotic lesions (?ﬁb.; c, f, i). Note the positive Kossa
reaction in the large ﬁbrotic area in (f) and the increase of cleaved
caspase-3 positive cells (arrowheads) within a ﬁbrotic lesion (le; i)o f
a DSG2
mt/mt mouse with ﬁbrosis. Scale bars: 5 mm in a (same
magniﬁcation in b, c), 200 lmi n( d) (same magniﬁcation in e, f),
100 lmi n( g) (same magniﬁcation in h, i)
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123to regions of epidermal desmoglein 3 that are targeted by
pemphigus autoimmune antibodies, which disrupt epider-
mal cell–cell adhesion [25, 62]. The reduced adhesiveness
of Dsg2
mt and the decreased desmosomal localization of
Dsg2
mt may therefore weaken intercalated discs and lead to
impaired force transmission making mutant hearts more
susceptible to microtraumata. Dsgs, however, also fulﬁll
functions in signaling. Thus, blockade of speciﬁc Dsg1 and
3 epitopes, which correspond to the region deleted in our
Dsg2 mutants, by pemphigus autoantibodies affects
signaling pathways involving p38, RhoA, protein kinase
Ca and cdk-2 in skin [6, 11, 36, 63]. Furthermore, loss of
desmosomal cadherins and associated proteins interferes
with wnt/b-catenin signaling [18, 28], which has been
implicated in DCM [26]. Further investigations are needed
to clarify the exact mechanism(s).
The DSG2
mt/mt mice helped to identify details of cardiac
disease before macroscopic and microscopic alterations
became apparent. Thus, c-myc and CTGF mRNAs were
already increased in 2-week-old mutant mice with
Fig. 7 Markers of heart failure
are increased in DSG2
mt/mt
mice. Cardiac ANF, BNF,
c-myc, CTGF and GDF15
mRNA expression was assessed
by real time RT-PCR in 2-,
8- and 13-week-old DSG2
wt/wt,
DSG2
wt/mt and DSG2
mt/mt mice.
Each column summarizes the
data of three to seven animals
(mean ± SEM).
Hydroxymethylbilane synthase
(HMBS) was used as
housekeeping gene control.
Unaltered regulator of G protein
signaling 2 (RGS2) mRNA
expression rules out a
systematic error of the RT-PCR
(p–r). Results of the post hoc
Bonferroni tests: *P\0.05,
**P\0.01, ***P\0.001.
Statistical analysis of mRNA
expression data showing no
signiﬁcant differences:
a P = 0.3409; d P = 0.0812;
g P = 0.1055; m P = 0.1466;
p P = 0.820; q P = 0.1837;
r P = 0.1623
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123seemingly normal heart muscle indicating early compen-
satory reactions of the heart to DSG2 gene mutation. In
accordance, it has been reported that c-myc and CTGF are
involved in the regulation of the cardiac hypertrophic
response and cardiac remodeling upon cardiac stress [16,
29, 35, 45]. In the presence of overt cardiomyocyte death
and ﬁbrosis, GDF15 mRNA expression was also found to
be signiﬁcantly elevated in 2-week-old mutants. GDF15 is
a reliable marker of heart failure in humans [31] and exerts
antihypertrophic and cardioprotective effects [32, 64]. This
observation can be taken as an indication of a later step of
disease progression, whereby altered cardiac wall compli-
ance is compensated for in addition to Dsg2 malfunction.
Disease progression and cardiac response were reﬂected by
further increase of the cardiac stress marker mRNAs and
the onset of mRNA synthesis of the natriuretic peptides
ANF and BNF in 8-week mutant animals, all of which
showed ﬁbrosis and cardiomyocyte death. ANF and BNF
effect diuresis and vasodilation and exert an antiﬁbrotic
activity in the heart [41, 43].
The ﬁbrotic response in the DSG2
mt/mt mice could be
subdivided into interstitial ﬁbrosis affecting the entire
heart muscle and focal ﬁbrosis or scarring. Interstitial cell
proliferation subsides in wild-type animals at 8 weeks,
when the heart reaches maturity [37]. In mutant mice,
however, the decline of interstitial cell proliferation rate
was postponed to the age of 13 weeks. The prolonged
interstitial cell proliferation may be a compensation for
the compromised Dsg2 function in force transmission at
the intercalated discs. In contrast to interstitial ﬁbrosis,
ﬁbrotic foci were characterized early on by Kossa-positive
cardiomyocytes indicative of necrotic calcinosis [34].
These foci appear in bursts during disease progression and
were observed as early as 2 weeks after birth and also
later on. Interestingly, similar cardiac necrosis was also
described in mice overexpressing a mutant human DSG2
gene [47]. These ﬁbrotic bursts may be induced by local
injuries of the heart muscle, which result initially in local
increase of ﬁbroblast proliferation and are coupled to
increased apoptosis as evidenced by elevated cleaved
caspase 3-staining and abundant cardiomyocyte necrosis.
Our ﬁndings further suggest that these active replacement
processes were terminated by the formation of inactive
scar tissue that was abundant in the older mutants. It will
be interesting to ﬁnd out whether the peculiar patterns of
ﬁbrosis can be correlated with the complex cardiac ﬁber
orientation and force distribution ﬁelds [30]. The pro-
nounced histomorphological alterations in cardiac archi-
tecture lead to increased wall stiffness and are responsible
for the right ventricular dilation that was observed at
autopsy and the pathological echocardiographic ﬁndings
of left ventricular dilation in combination with systolic
and diastolic dysfunction. Biventricular dilation probably
plays a major part in triggering arrhythmias leading to
premature death.
Taken together, the DSG2
mt/mt mice revealed major
features of desmosome-related cardiomyopathies. Further
assessment will clarify steps of disease initiation and pro-
gression and will help to develop and test therapeutic
strategies for treatment of human DCM and ARVC.
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Table 3 Cardiac cytokine mRNA expression in relation to ﬁbrosis in 2-week-old DSG2-mutant mice
Cytokine mRNA wt/wt (n = 3) mt/wt (n = 4) mt/mt - ﬁbr. (n = 4) mt/mt ? ﬁbr. (n = 3) ANOVA
ANF 0.26 ± 0.14 1.12 ± 0.63 0.64 ± 0.25 1.82 ± 0.27 0.1371
BNF 0.34 ± 0.05 0.87 ± 0.15 1.13 ± 0.32 1.59 ± 0.54 0.1196
c-myc 0.40 ± 0.09 0.47 ± 0.04 1.14 ± 0.48 2.04 ± 0.81 0.1006
CTGF 0.12 ± 0.04 0.18 ± 0.01 0.34 ± 0.07 0.53 ± 0.15* 0.0191
GDF15 0.18 ± 0.03 0.31 ± 0.09 0.82 ± 0.30 3.83 ± 1.42*
,**
,? 0.0083
RGS2 0.69 ± 0.10 0.77 ± 0.24 0.85 ± 0.15 0.76 ± 0.07 0.9015
The results of cytokine RT-PCR analyses in hearts of wild-type (wt/wt), heterozygous (mt/wt) and homozygous DSG2-mutant mice (mt/mt) are
summarized. The homozygous mutant mice are further subclassiﬁed into those with severe cardiac ﬁbrosis (mt/mt ? ﬁbr.) and those without
visible cardiac ﬁbrosis (mt/mt - ﬁbr.). Data are given as mean ± SEM. Note the signiﬁcantly elevated GDF15 mRNA in the homozygous
mutant animals with ﬁbrotic foci
* wt/wt versus mt/mt ? ﬁbr. P\0.05
** mt/wt versus mt/mt ? ﬁbr. P\0.05
? mt/mt - ﬁbr. versus mt/mt ? ﬁbr. P\0.05
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